Seqens Seqens

X
[{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BPL Receives Orphan Drug Marketing Authorization for Coagadex\u00ae in Mexico","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"CSI Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSI Pharmacy Announces Limited Distribution Agreement for Gammaplex","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Bio Products Laboratory

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, CSI Pharmacy will get access for limited distribution rights to BPL's immune globulin product Gammaplex® (human immunoglobulin). Immune globulin products contain human antibodies, derived primarily from donated human plasma.

            Lead Product(s): Human Immunoglobulin

            Therapeutic Area: Immunology Product Name: Gammaplex

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: CSI Pharmacy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Coagadex® is the first and only treatment specifically for Hereditary Factor X Deficiency, a very rare inherited clotting disorder that causes problems with blood clotting due to not having enough Factor X in the blood.

            Lead Product(s): Coagulation Factor X (Human)

            Therapeutic Area: Hematology Product Name: Coagadex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY